Summit Corporation PLC

Type: Company
Name: Summit Corporation PLC
First reported Jul 30 2014 - Updated 20 hours ago - 3 reports

Summit chief buys 30,000 shares

AIM-listed drug developer Summit, which develops therapies for Duchenne Muscular Dystrophy and C. difficile infection, on Wednesday said its chief executive Glyn Edwards had acquired 30,000 shares.The 104.5p-a-share deal cost Edwards £31,350 and took ... [Published London South East - 20 hours ago]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Summit Corporation climbs as CEO ups stake

Shares in drug discovery firm Summit ( LON:SUMM ) advanced early on Wednesday as it emerged chief executive Glyn Edwards has upped his stake. Edwards bought 30,000 shares at 104.5p a pop, taking his holding to 233,333 shares, representing 0.57% of the ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 30 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 2 reports

Summit Corporation PLC Summit Corporation Plc : Update On Capital..

TIDMSUMM Summit Corporation plc ('Summit' or the 'Company') UPDATE ON CAPITAL REORGANISATION Oxford, UK, 18 July 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile ... [Published ADVFN UK - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Summit Corporation PLC : Summit Corporation PLC : Award of Share Options

Summit Corporation plc('Summit' or the 'Company')AWARD OF SHARE OPTIONSOxford, UK, 16 July 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, announce ... [Published Investegate - Jul 16 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Proactive news summary - Roxi Petroleum, Mwana Africa, Ortac, Sula Iron & Gold, Iofina, Summit Corp, Alliance Pharma, Ascent Resources, Providence, Victoria Oil & Gas

Roxi Petroleum ( LON:RXP ) virtually doubled in price after news of a discovery at its flagship BNG asset in Kazakhstan. Results from Mwana Africa ( LON:MWA ) got the thumbs-up early on though gains  were clawed back later. Underlying earnings (EBITDA) ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 4 reports

Summit Corporation plc Antibiotic Eligible For Fast Track

The Oxford based drugmaker Summit Corporation (LSE: SUMM) announced today that the antibiotic SMT19969 has been designated by the US regulator as a Qualified Infectious Disease Product ('QIDP').The drug, which treats C. difficile infection, is therefore ... [Published Yahoo! UK and Ireland - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Broker Spotlight - Shire, Ophir, Providence Resources, Victoria Oil & Gas, Blur Group, Summit Corp

AbbVie’s newly raised US$51bn offer should be sufficient to get Shire’s () management to the negotiating table, says UBS analyst Guillaume van Renterghem.Van Renterghem reckons yesterday’s cash-and-share offer, which with a value of £51.15 per Shire share ... [Published Proactive Investors.co.uk - Jul 09 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 2 reports

Summit Sees Positive Duchenne Muscular Dystrophy Drug Trial Results

LONDON ( Alliance News ) - Summit Corp PLC said Monday it has seen encouraging results from its Phase 1b trial of its duchenne muscular dystrophy treatment SMT C1100.Duchenne muscular dystrophy is a genetic condition that causes muscle weakness.The treatment ... [Published 4 Traders - Jul 07 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 2 reports

Market report: Serco ditched for DLR

Troubled outsourcing business Serco ( SRP ) continues its run of bad luck, down 0.7% to 360.5p as it fails to keep the Docklands Light Railway management contract. It has run the shuttle service in London since 1997 but has now failed to snag the franchise ... [Published Shares Magazine - Jul 04 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

AIM Notice - 04/07/2014

04/07/2014 - 8:00amThe London Stock Exchange admits the following securities to trading on AIM:CAZA OIL & GAS INC COMMON SHARES OF NO PAR VALUE, FULLY PAID, (CDI) CENTRAL ASIA METALS PLC ORDINARY SHARES OF USD0.01 EACH, FULLY PAID CONCHA PLC ORDINARY ... [Published MoneyAM - Jul 04 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 2 reports

Summit Corporation PLC : Summit Corporation PLC : Result of AGM

Summit Corporation plc('Summit' or the 'Company')ANNUAL GENERAL MEETING RESULTSOxford, UK, 3 July 2014 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces ... [Published Investegate - Jul 03 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 2 reports

Summit updates on Phase 2 trial of Novel C

Summit Corp, a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection ('CDI'), said the first patients have been dosed in its Phase 2 proof of concept clinical trial that is evaluating the ... [Published MoneyAM - Jul 03 2014]

Quotes

...that, on 29 July 2014, Glyn Edwards, Chief Executive Officer of the Company, acquired 30,000 ordinary shares of 1 penny each ("Ordinary Shares ") in the Company at a price of 104.5 pence per Ordinary Share."
TIDMSUMM Summit CorporationSummit Corporation plc ( "Summit' or the 'Company') UPDATE ON CAPITAL REORGANISATION Oxford, UK, 18 July 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C difficile infection, today provides an update on the timetable relating to the cancellation of deferred shares and reduction of share premium account that were announced on 2 June 2014. There has been a change in the dates for the Court hearing to approve the cancellation of all deferred shares that are in existence and the reduction in the share premium account. The change in dates is due to convening a second ClassClass Meeting of the holders of the deferred shares that were in existence prior to the Company's AGM on 3 July 2014. The meeting will seek to gain the necessary consent to cancel those deferred shares. The new expected timetable of events is outlined below: Event 2014 Expected date of Court hearing to confirm the Capital 3 September Reduction Expected effective final date for the CapitalCapital Reduction 4 September Further announcements will be made as appropriate. - END - Notes to Editors About Summit Summit is an Oxford, UK based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C difficile infection. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc https://twitter.com/Summitplc ). For more information, please contact: Summit Tel: +44 (0)1235 443 951 Glyn Edwards / Richard Pye Cairn Financial Advisers LLP Tel: +44 (0)20 7148 7900 (Nominated Adviser) Liam Murray / Tony Rawlinson N+1 Singer Tel: +44 (0)20 7496 3000 (Broker) Aubrey Powell / Jen Boorer Peckwater PR (Financial public relations, UK) Tel: +44 (0)7879 458 364 Tarquin Edwards tarquin.edwards@peckwaterpr.co.uk MacDougall Biomedical Communications Tel: +1 781-235-3060 (US media contact) Michelle Avery This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Summit Corporation PLC via Globenewswire HUG#1831013 http://www.summitplc.com/"
Oxford, UK, 16 July 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ( "DMD') and C difficile infection, announce that on 15 July 2014 it granted Share Options over 1,458,341 shares to Executive Directors, Non-Executive Directors, and other members of the Company under the existing Company Share Option Plan at an exercise price of 126 pence per share (being the mid-market closing price of a Summit ordinary share on 14 July 2014). The details of the award to Executive and Non-Executive Directors and Officers are as follows:"
"This status recognises the serious healthcare threat posed by pathogens such as C difficile and it will confer a number of advantages that will accelerate the development of this promising and differentiated antibiotic with the potential to treat initial CDI and reduce the high rates of disease recurrence, the major clinical issue."

More Content

All (47) | News (45) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Summit chief buys 30,000 shares [Published London South East - 20 hours ago]
Summit Corporation climbs as CEO ups stake [Published Proactiveinvestors United Kingdom RSS feed - Jul 30 2014]
Summit Corporation PLC : Director/PDMR Sharehol... [Published Investegate - Jul 30 2014]
REG-Director/PDMR Shareholding [Published Reuters - Jul 30 2014]
Summit Corporation PLC Summit Corporation Plc :... [Published ADVFN UK - Jul 18 2014]
Summit Corporation PLC : Update on Capital Reor... [Published MoneyAM - Jul 18 2014]
Summit Corporation PLC : Summit Corporation PLC... [Published Investegate - Jul 16 2014]
Research breakthroughs and deal speculation put... [Published Proactiveinvestors United Kingdom RSS feed - Jul 12 2014]
SMALL CAP MOVERS: Proteome Sciences shares' rec... [Published This Is Money - Jul 11 2014]
Proactive news summary - Roxi Petroleum, Mwana ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
Summit Corporation plc Antibiotic Eligible For ... [Published Yahoo! UK and Ireland - Jul 09 2014]
UPDATE - Summit Corp antibiotic could be fast-t... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
Broker Spotlight - Shire, Ophir, Providence Res... [Published Proactive Investors.co.uk - Jul 09 2014]
Summit says FDA grants QIDP designation to SMT1... [Published MoneyAM - Jul 09 2014]
Summit Corp antibiotic could be fast-tracked un... [Published Proactiveinvestors United Kingdom RSS feed - Jul 09 2014]
Summit Sees Positive Duchenne Muscular Dystroph... [Published 4 Traders - Jul 07 2014]
Summit Presents New Data from Phase 1b Clinical... [Published EuroInvestor - Jul 07 2014]
FTSE 100 up on miners, retailers as airlines fe... [Published Stock Market Wire - Jul 04 2014]
Market report: Serco ditched for DLR [Published Shares Magazine - Jul 04 2014]
FTSE mixed as resources, financial stocks weigh [Published MoneyAM - Jul 04 2014]
AIM Notice - 04/07/2014 [Published MoneyAM - Jul 04 2014]
Summit Corporation PLC : Summit Corporation PLC... [Published Investegate - Jul 03 2014]
Summit Corporation PLC Summit Corporation Plc :... [Published ADVFN UK - Jul 03 2014]
Summit updates on Phase 2 trial of Novel C [Published MoneyAM - Jul 03 2014]
Summit Corporation PLC Summit Announces First P... [Published ADVFN UK - Jul 03 2014]
Summit Corporation Appoints Erik Ostrowski As C... [Published FierceBiotech - Jun 27 2014]
Summit Corporation PLC : Share Option Awards [Published FinanzNachrichten.de - Jun 24 2014]
Summit Corporation Appoints As Chief Financial ... [Published BioSpace - Jun 24 2014]
What's Market weekly industry sector deal activ... [Published Practical Law Company - Jun 23 2014]
Algird J. Brazauskas|Former president of Summit... [Published Waterbury Republican American - Jun 22 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FTSE 100 ends Monday higher thanks to miners an... [Published Proactiveinvestors United Kingdom website - May 12 2014]
London’s blue-chips closed Monday around a half percent better, as blue-chip mining stocks helped sentiment. By the close, the FTSE 100 index was 37 points, 0.55%, higher – changing hands at around 6,851. Takeovers in the drug business also continue ...
Are European investors falling in love with bio... [Published Proactiveinvestors United Kingdom website - Feb 14 2014]
America’s love affair with biotechnology is well charted. In the last three years it has been the best performing investment sector, supported by the success of smaller research-led firms and the continued growth of some of the industry’s bigger hitters. ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.